<DOC>
	<DOCNO>NCT01808820</DOCNO>
	<brief_summary>Dendritic Cell vaccine manufacture partially mature use standard operating procedure , develop collaboration HGG Immuno Group , administer imiquimod treat skin safe feasible patient high grade glioma . This result anti-tumor immunity prolong survival subject treat . Study treatment correlate laboratory evidence immune activation .</brief_summary>
	<brief_title>Dendritic Cell ( DC ) Vaccine Malignant Glioma Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Age : ≥ 13 year ≤ 99 year . 2 . ( 2a ) Relapse high grade glioma ( anaplastic astrocytoma World Health Organization ( WHO ) grade III glioblastoma multiforme WHO grade IV ) , histologically prove first stage disease ( radiological evidence recurrence suffices ) ; OR ( 2b ) Relapse glioma , grade II initial diagnosis , grade III IV relapse base radiological pathological criterion . 3 . Total subtotal resection tumor mass , confirm assessment neurosurgeon postoperative MRI scan within 72 hour surgery . The postoperative assessment demonstrate residual tumor less equal 2 cm^3 judge surgeon MRI tumor show linear contrast enhancement border resection cavity nodule le 2 cm^3 . 4 . No radiotherapy and/or chemotherapy receive least 1 month first DC vaccination administer 5 . No treatment corticosteroid salicylates least 1 week first vaccination . Corticosteroid therapy rapidly wean within 12 week surgery . 6 . Life expectancy &gt; 3 month . 7 . Written consent patient parent ( ) ( patient &lt; 18 year ) institutional review board ( IRB ) approve informed consent form prior studyspecific evaluation . Assent required child per University Miami ( UM ) IRB guideline . Subject must capable understanding investigational nature , potential risk benefit study able provide valid inform consent . 8 . Adequate organ function ( measure enrollment ) Absolute neutrophil count ( ANC ) ≥ 750/L Lymphocytes ≥ 500/L Platelets ≥ 75,000/L Hemoglobin ≥ 9 g/dL Aspartate transaminase ( AST ) /Alanine transaminase ( ALT ) ≤ 2.5 X upper limit normal ( ULN ) ; liver metastasis , ≤ 5 X ULN Serum Creatinine ≤ 1.5 X ULN Total Bilirubin ≤ 3 X ULN Albumin &gt; 2 g/dL 9 . Subjects must agree use adequate method contraception abstinence throughout 4 week study treatment completion . 10 . Karnofsky score 70 high Eastern Cooperative Oncology Group ( ECOG ) status 0 1 . 1 . Pregnancy . 2 . Breast feeding female . 3 . Any concomitant participation therapeutic trial . 4 . Virus serology positive HIV ( test require absence clinical suspicion ) . 5 . Documented immunodeficiency autoimmune disease . 6 . Mandatory treatment corticosteroid salicylates week prior first vaccination . 7 . Other active malignancy . 8 . Patients unresectable tumor , instance pontine glioma , exclude . 9 . Refusal use adequate contraception fertile patient ( female male ) study 30 day last dose study treatment . 10 . Any serious uncontrolled medical psychiatric condition opinion investigator make patient able participate study . 11 . Application gliadel wafer within prior 4 month plan place gliadel wafer time resection tumor acquisition study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malignant Glioma</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>High Grade Glioma</keyword>
	<keyword>HGG</keyword>
	<keyword>Dendritic Cell Vaccine</keyword>
	<keyword>DC Vaccine</keyword>
	<keyword>Leukapheresis</keyword>
</DOC>